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Suwon, and Seongnam, Republic of KoreaObjectives This study sought to test the noninferiority of triple antiplatelet therapy (TAT) versus
double-dose clopidogrel dual antiplatelet therapy (DDAT) in patients undergoing percutaneous
coronary intervention (PCI).
Background Antiplatelet regimen is an integral component of medical therapy after PCI. A 1-week
duration of doubling the dose of clopidogrel was shown to improve outcome at 1 month compared
with the conventional dose in patients with acute coronary syndrome undergoing PCI. Yet in Asia, the
addition of cilostazol is used more commonly than DDAT in high-risk patients.
Methods We randomly assigned 3,755 all-comers undergoing PCI to either TAT or DDAT, which was
continued for 1 month, to test the noninferiority of TAT versus DDAT. The primary outcome was the
cumulative incidence of net clinical outcome at 1 month post-PCI deﬁned as the composite of cardiac
death, nonfatal myocardial infarction, stent thrombosis, stroke, and PLATO (Platelet Inhibition and
Patient Outcomes) major bleeding.
Results TAT was noninferior to DDAT with respect to the primary outcome, which occurred in 1.2% and
1.4% of patients, respectively (0.22% absolute difference, 0.34% 1-sided 97.5% conﬁdence interval, p¼
0.0007 for noninferiority; hazard ratio: 0.85; 95% conﬁdence interval: 0.49 to 1.48; p ¼ 0.558 for
superiority). The individual risks of cardiac death, nonfatalmyocardial infarction, stent thrombosis, stroke,
and PLATO major bleeding did not differ signiﬁcantly between the 2 groups. There were no signiﬁcant
between-group differences in the treatment effect with regard to the rate of the primary outcome.
Conclusions The adjunctive use of cilostazol was noninferior to doubling the dose of clopidogrel for 1
month in all-comers undergoing PCI with exclusively drug-eluting stents. (Harmonizing Optimal
Strategy for Treatment of Coronary Artery Stenosis–SAfety & EffectiveneSS of Drug-ElUting Stents &
Anti-platelet REgimen [HOST-ASSURE]; NCT01267734) (J Am Coll Cardiol Intv 2013;6:932–42) ª 2013
by the American College of Cardiology FoundationFrom the *Seoul National University Hospital, Seoul, Republic of Korea; yDankook University Hospital, Cheonan, Republic of
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933Antiplatelet regimen is an integral component of medical
therapy after percutaneous coronary intervention (PCI). In
to either platinum-chromium–based everolimus-eluting stentsparticular, the inhibition of platelet reactivity in the ﬁrst
month post-PCI is known to be critical in preventing
thrombotic events (1) because high on-treatment platelet
reactivity (HOPR) is reported to be associated with higher
risk of thrombotic cardiovascular events such as cardio-
vascular death, myocardial infarction (MI), stroke, and
stent thrombosis (2–6). One week of doubling the dose of
clopidogrel was shown to improve outcome at 1 month
compared with the conventional dose in acute coronarySee page 943
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and Acronyms
ACS = acute coronary
syndromes
CI = conﬁdence interval
PCI = percutaneous coronary
intervention
HOPR = high on-treatment
platelet reactivity
OPR = on-treatment
platelet reactivity
TAT = triple antiplatelet
therapy
DDAT = double-dose
clopidogrel dual
antiplatelet therapy
MI = myocardial infarctionsyndrome (ACS) patients undergoing PCI in the
CURRENT–OASIS (Clopidogrel and Aspirin Optimal
Dose Usage to Reduce Recurrent Events–Seventh Or-
ganization to Assess Strategies in Ischemic Syndromes)
7 trial (7). Yet in East Asia, the addition of cilostazol to
dual antiplatelet therapy (triple antiplatelet therapy
[TAT]) is used more commonly than doubling the dose of
clopidogrel (double-dose dual antiplatelet therapy,
[DDAT]). In addition, pharmacodynamic studies and some
observational studies showed promising results with regard to
the adjunctive use of cilostazol (8–12). However, there has been
no large-scalehead-to-headcomparisonofTATwithDDAT to
date with regard to clinical outcome. The purpose of the
present study was to generate evidence of the rationale for
using TAT in patients undergoing PCI by conﬁrming the
noninferiority of TAT compared with DDAT at 1 month
post-PCI in a nearly all-comer population undergoing PCI
with exclusively drug-eluting stents.
Methods
Study design and patients. The HOST-ASSURE (Harmo-
nizing Optimal Strategy for Treatment of Coronary Artery
Stenosis–Safety & Effectiveness of Drug-Eluting Stents
& Anti-platelet Regimen) trial was a prospective, randomized,
blinded endpoint evaluation, multicenter trial conducted at 40
sites in the Republic of Korea. The study design was previously
published (13). Brieﬂy, the study had a 2 2 factorial design in
which randomization was performed for the type of drug-
eluting stent and type of antiplatelet therapy. Participating
patientswere randomized 1:1 to eitherTATorDDATand 2:1Changwon Hospital, Changwon, Republic of Korea; **Chonnam National University
Hospital, Gwangju, Republic of Korea; yyBoramae Medical Center, Seoul, Republic
of Korea; zzChungbuk National University Hospital, Cheongju, Republic of Korea;
xxWonju Christian Hospital, Wonju, Republic of Korea; kkInje University Ilsan Paik
Hospital, Goyang, Republic of Korea; {{Dong-A Medical Center, Busan, Republic
of Korea; ##St. Vincent’s Hospital, Suwon, Republic of Korea; ***Gangnam Severance
Hospital, Seoul, Republic of Korea; and the yyySeoul National University Bundang
Hospital, Seongnam, Republic of Korea. This study was supported by a grant from theor cobalt-chromium–based zotarolimus-eluting stents. The
trial was coordinated by the investigators at the Cardiovascular
Clinical Research Center at Seoul National University Hos-
pital. The data were independently managed by a contract
research organization (Dream CIS Inc., Seoul, Republic of
Korea). The primary data analysis was performed by the
investigators with cooperation from Dream CIS Inc. The
executive committee, with assistance from the steering
committee, was responsible for the study design, conduct,
management, manuscript preparation, and decision to submit
the manuscript for publication. The corresponding author had
full access to all the data in the study and had ﬁnal responsibility
for the decision to submit for publication.An independent data
safety monitoring board reviewed the unblinded data. The
study was approved by all local ethics committees at the
participating centers, performed in accordance with the
Declaration of Helsinki, and all participants provided written
informed consent. All authors
vouch for the accuracy and
completeness of the data and
analyses.
Patients. Trial participants were
18 years of age or older and had
at least 1 clinically signiﬁcant
stenotic lesion amenable to PCI
in the coronary artery or venous
or arterial bypass grafts. The trial
entry criteria were broad with no
exclusion criteria for lesion type,
the number of stents used, the
number of lesions treated, or the
diagnosis at presentation. Major
exclusion criteria were severe left
ventricular systolic dysfunction
(ejection fraction <25%), car-
diogenic shock, an increased risk of bleeding as evidenced by
a history of bleeding diathesis, known coagulopathy, gastro-
intestinal or genitourinary bleeding within the previous 3
months, or major surgery within 2 months. Details of the
eligibility criteria are described in the Online Appendix.
Study procedures and follow-up. Patients were randomly
assigned to receive either TAT or DDAT, and PCI was
performed according to the standard techniques. Before the
index PCI, all patients received loading doses of 300 mgInnovative Research Institute for Cell Therapy, Seoul National University Hospital
(A062260), sponsored by the Ministry of Health and Welfare, Republic of Korea. The
authors also received an unrestricted grant from Boston Scientiﬁc Korea. The funding
sources of the study had no role in study design, data collection, monitoring, analysis,
interpretation, or writing of the paper. Drs. Park and Kang contributed equally to this
study.
Manuscript received February 12, 2013; revised manuscript received March 27, 2013,
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934aspirin and 300 to 600 mg clopidogrel. Patients randomized
to the TAT group received an additional loading of 200 mg
cilostazol (Otsuka Pharmaceutical, Seoul, Republic of
Korea) followed by twice-daily 100-mg maintenance dose
for 1 month. Those randomized to the DDAT group were
maintained on a 150-mg/day maintenance dose of clopi-
dogrel for 1 month. Unfractionated heparin was adminis-
tered throughout the procedure to maintain an activated
clotting time of 250 s. Administration of glycoprotein IIb/
IIIa inhibitors was at the discretion of the treating physician.
After the procedure, all patients were recommended to
receive optimal pharmacological therapy including statins,
beta-blockers, angiotensin-converting enzyme inhibitors,
and angiotensin receptor blockers at the discretion of the
treating clinicians. Additionally, each investigator was
advised to emphasize the importance of cardiovascular risk-
factor modiﬁcation to patients.
Outcomes. The primary endpoint was net clinical outcome,
deﬁned as a composite of cardiac death, nonfatal myocardial
infarction, stent thrombosis, stroke, and PLATO (Platelet
Inhibition and Patient Outcomes) (14) major bleeding at
1 month. Secondary endpoints included all of the individual
components of the primary composite endpoint along with
all death, PLATO minor bleeding, target lesion revascu-
larization, and target vessel revascularization. Clinical events
were deﬁned on the basis of the recommendations of the
Academic Research Consortium (15). All deaths were
considered cardiac unless a deﬁnite noncardiac cause could
be established. MI was deﬁned as the presence of clinical
signs of MI combined with a creatine kinase-myocardial
band fraction or troponin T/troponin I increase higher than
the upper normal limit. Stent thrombosis was deﬁned as
deﬁnite or probable stent thrombosis according to the
Academic Research Consortium classiﬁcation. Stroke, as
detected by the occurrence of a new neurological deﬁcit, was
conﬁrmed by a neurologist and on imaging. PLATO major
bleeding included life-threatening major bleeding (fatal,
intracranial, or intrapericardial bleed with cardiac tampo-
nade or hypovolemic shock or severe hypotension requiring
pressors or surgery, associated decrease in hemoglobin >50
g/l, or transfusion of 4 U of whole blood or packed red
blood cells) or other major bleeding (signiﬁcantly disabling
bleeding such as intraocular bleeding with permanent vision
loss, associated decrease in hemoglobin 30 to 50 g/dl, or
transfusion of 2 to 3 U of whole blood or packed red blood
cells). An independent clinical event adjudication
committee, whose members were unaware of the study
group assignments, assessed all of the clinical endpoints. All
endpoints were analyzed on an intention-to-treat basis. In
the secondary per-protocol analysis, patients who were
adhering to allocated therapy at 1-month clinical follow-up,
as well as those adhering to allocated therapy at the occur-
rence of clinical events were included in the analysis. In
a subgroup of patients, platelet function tests using theVerifyNow P2Y12 assay were performed at baseline (12 to 24
h after a loading dose of clopidogrel 300 to 600 mg with or
without cilostazol 200 mg) and at 1-month follow-up under
maintenance dose (clopidogrel 75 to 150 mg/day with or
without cilostazol 100 mg twice daily). The assay at follow-
up after maintenance dose treatment was recommended to
be performed 2 to 6 h after administration of the morning
dose.
Statistical analysis. With the assumption that the primary
outcome rate would be 2% and 3% in the TAT and DDAT
group, respectively, we estimated that 3,750 patients would
be required for the study to have >90% power to show
noninferiority of TAT at an alpha of 2.5% and a non-
inferiority margin of 0.75%. The primary analysis was per-
formed on an intention-to-treat basis. Continuous variables
were presented as mean (SD) and compared using the
Student t test. Categorical variables were presented as counts
and percentages and compared using the chi-square or
Fisher exact test, as appropriate. Time to ﬁrst event was
estimated using the Kaplan-Meier method. If the upper
limit of a 1-sided 97.5% conﬁdence interval (CI) of the
difference was less than the pre-speciﬁed noninferiority
margin, TAT would be considered to be noninferior to
DDAT. Time-to-event curves were compared using the
log-rank tests. Hazard ratios with 95% CIs were estimated
using the Cox proportional hazards method. The consis-
tency of treatment effects in pre-speciﬁed subgroups was
assessed using Cox regression models with tests for inter-
action. p Values and CIs were 2-tailed except those for
noninferiority testing of the primary endpoint. We also
performed per-protocol analysis among patients who
adhered to the study protocol. All analyses were performed
using SAS version 9.1 (SAS Institute, Cary, North
Carolina).
Results
Characteristics of study patients. From June 2010 to
November 2011, we enrolled 3,755 patients from 40 centers
in the Republic of Korea. These patients were randomly
assigned to TAT (n ¼ 1,879) or DDAT (n ¼ 1,876). The
ﬂow of the patients enrolled is shown in Figure 1. The
baseline characteristics were mostly well balanced between
the randomized groups, except mean age and the frequency
of a history of MI, which was slightly higher, and the
frequency of peripheral arterial disease, which was slightly
lower in the DDAT group (Table 1). There were no
differences in hemoglobin, platelet count, and low-density
lipoprotein cholesterol levels between the 2 groups. The
baseline procedural characteristics and the use of nonstudy
medications up to 1 month of follow-up were also mostly
well balanced between the 2 groups, except for the use of
calcium channel blockers, which was slightly higher in the
DDAT group (Table 2). Of the patients, 65.5% presented
Figure 1. Trial Proﬁle
A total of 3,755 patients were randomly assigned to either triple antiplatlet therapy (n ¼ 1,879) or double-dose clopidogrel dual antiplatelet therapy (n ¼ 1,876). The
analysis was performed on an intention-to-treat basis. DDAT ¼ double-dose clopidogrel dual antiplatelet therapy; TAT ¼ triple antiplatelet therapy.
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935with ACS, 53.8% had multivessel disease, 3% underwent
PCI for signiﬁcant left main disease, and 16.2% patients
underwent PCI for bifurcation lesions reﬂecting the all-
comer nature of the patients enrolled in the study.
Clinical outcome. The primary endpoint of net clinical
outcome at 1 month post-PCI, a composite of cardiac death,
nonfatal MI, stent thrombosis, stroke, and PLATO major
bleeding, occurred in 23 patients (1.2%) in the TAT group
and 27 patients (1.4%) in the DDAT group (Table 3,
Fig. 2). We conﬁrmed the noninferiority of TAT with an
absolute risk difference of 0.22% and an upper limit of the
1-sided 97.5% CI of 0.52% (p ¼ 0.005 for noninferiority;
prespeciﬁed noninferiority margin, 0.75%). Regarding
superiority, there was no signiﬁcant difference between the
2 treatment groups (hazard ratio: 0.85; 95% CI: 0.49 to
1.48; p ¼ 0.558 for superiority). The rates of the individual
components of the primary endpoint showed similar trends.
The risks of cardiac death, nonfatal MI, stent thrombosis,
stroke, and PLATO major bleeding did not differ signi-
ﬁcantly between the 2 groups. There was no signiﬁcant
interaction between the antiplatelet regimen and stent
randomization arms regarding any study outcomes. In alandmark analysis at 1 week, there were no differences
between the 2 groups regarding the primary endpoint or the
major secondary endpoints (Fig. 3). The rates of PLATO
major bleeding were the same in TAT and DDAT groups.
PLATO minor bleeding rates were not statistically different,
but numerically higher, and occurred in 6 more patients in
the TAT group. Subgroup analyses for the primary outcome
showed no signiﬁcant interaction between different sub-
group including clopidogrel loading dose and the treatment
effect of TAT versus DDAT (Fig. 4).
Compliance with study regimen and per-protocol analysis. After
randomization, allocated therapy was given in 97.4% of the
patients allocated to the TAT group and 92.2% in the DDAT
group, respectively (p < 0.001). Of the patients allocated to
DDAT, 5.2% refused the additional dose of clopidogrel. Up
to 1-month follow-up, an additional 5.8% of patients in the
TAT group and 5.7% in the DDAT group were nonadherent
to the allocated treatment during 1 month of follow-up after
enrollment (p ¼ NS). Therefore, at 1-month follow-up, the
adherence rates in the TAT and DDAT groups were 91.6%
and 86.5%, respectively (p < 0.001). Drug-related adverse
events were the major reason for discontinuation of medication
Table 1. Baseline Patient Characteristics
Characteristic
TAT
(n ¼ 1,879)
DDAT
(n ¼ 1,876) p Value
Age, yrs 62.8  10.7 63.7  10.9 0.007
Men 1,311 (69.8) 1,257 (67.0) 0.068
Body mass index, kg/m2 24.7  3.2 24.6  3.1 0.237
Hypertension 1,256 (66.8) 1,286 (68.6) 0.264
Diabetes 598 (31.8) 588 (31.3) 0.751
Insulin-requiring diabetes 66 (3.5) 71 (3.8) 0.657
Dyslipidemia 1,206 (64.2) 1,176 (62.7) 0.341
Current smoker 616 (32.8) 577 (30.8) 0.182
Chronic renal failure 42 (2.2) 50 (2.7) 0.394
Peripheral artery disease 44 (2.3) 24 (1.3) 0.015
Cerebrovascular disease 120 (6.4) 128 (6.8) 0.590
Previous PCI 188 (10.0) 181 (9.6) 0.713
Previous bypass surgery 11 (0.6) 15 (0.8) 0.429
Previous myocardial infarction 69 (3.7) 96 (5.1) 0.031
Previous congestive heart failure 23 (1.2) 31 (1.7) 0.270
Clinical diagnosis 0.786
Silent ischemia 96 (5.1) 86 (4.6)
Stable angina 564 (30.0) 549 (29.3)
Unstable angina 690 (36.7) 688 (36.7)
NSTEMI 328 (17.5) 332 (17.7)
STEMI 201 (10.7) 221 (11.8)
Baseline laboratory ﬁndings
Left ventricular ejection fraction, % 60.3  10.3 59.9  10.3 0.282
Hemoglobin, g/dl 13.7  1.8 13.7  1.7 0.532
Platelet count, 103/mm 227  63 227  61 0.840
Serum creatinine, mg/dl 1.0  0.8 1.0  0.8 0.722
Total cholesterol, mg/dl 178  44 177  44 0.268
Triglyceride, mg/dl 143  93 136  95 0.029
HDL cholesterol, mg/dl 44  12 44  11 0.941
LDL cholesterol, mg/dl 110  42 109  38 0.503
Medications at discharge
Aspirin 1,867 (99.4) 1,862 (99.3) 0.691
Clopidogrel 1,866 (99.3) 1,863 (99.3) 0.997
Beta-blocker 1,277 (68.0) 1,277 (68.1) 0.943
Calcium-channel blocker 357 (19.0) 407 (21.7) 0.040
ACE inhibitor or ARB 1,215 (64.7) 1,248 (66.5) 0.230
CYP3A4-metabolized statin 1,032 (54.9) 1,060 (56.5) 0.330
Non–CYP3A4-metabolized statin 545 (29.0) 559 (29.8) 0.594
Proton pump inhibitor 153 (8.1) 148 (7.9) 0.779
Values are mean  SD or n (%).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; CYP ¼ cytochrome P450; HDL ¼ high-density lipoprotein;
LDL ¼ low-density lipoprotein; NSTEMI ¼ non–ST-segment elevation myocardial infarction; PCI ¼ percutaneous coronary intervention;
STEMI ¼ ST-segment elevation myocardial infarction.
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936in the TAT group (i.e., namely headache, followed by easy
bruisability or bleeding, gastrointestinal side effects, skin rash,
and tachycardia). In the DDAT group, the major reasons for
drug-related adverse events were gastrointestinal side effects and
easy bruisability. In the per-protocol analysis, the primary
outcome occurred in 1.2% in the TAT group and 1.6% in
the DDAT group (0.43% absolute risk difference, 0.37%
1-sided 97.5% upper CI, p ¼ 0.002 for noninferiority; hazardratio: 0.73; 95% CI: 0.42 to 1.30, p ¼ 0.287 for superiority)
(Online Table 2). There were also no signiﬁcant differences in
the individual components of the primary endpoint as well as
other secondary endpoints. However, spontaneous MI occurred
more frequently in theDDATgroup in the per-protocol analysis.
Platelet function test. In a subgroup of patients (n ¼ 1,356,
36.1%), platelet reactivity was measured using the VerifyNow
P2Y12 assay. The mean on-treatment platelet reactivity
Table 2. Angiographic and Procedural Characteristics
Variable
TAT
(n ¼ 1,879)
DDAT
(n ¼ 1,876) p Value
Angiographic disease extent 0.631
1 vessel 856 (45.6) 877 (46.7)
2 vessel 618 (32.9) 590 (31.4)
3 vessel 405 (21.6) 409 (21.8)
No. of lesions treated per patient 1.5  0.8 1.5  0.8 0.639
Stent arm: intention-to-treat 0.972
Promus-Element arm 1,253 (66.7) 1,250 (66.6)
Endeavor-Resolute arm 626 (33.3) 626 (33.4)
Type of drug-eluting stents – per protocol 0.552
No stents used 14 (0.7) 9 (0.5)
Promus-Element 1,198 (63.8) 1,202 (64.1)
Endeavor-Resolute 587 (31.2) 573 (30.5)
Other 80 (4.3) 92 (4.9)
No. of stents per patient 1.6  0.9 1.6  0.9 0.513
Use of IVUS or OCT 737 (39.2) 763 (40.7) 0.365
Treatment of left main disease 57 (3.0) 55 (2.9) 0.852
Treatment of bifurcation lesions 308 (16.4) 303 (16.2) 0.842
Use of glycoprotein IIb/IIIa inhibitors 46 (2.4) 50 (2.7) 0.673
Values are n (%) or mean  SD.
DDAT ¼ double-dose clopidogrel antiplatelet therapy; IVUS ¼ intravascular ultrasound; OCT ¼ optical coherence tomography; TAT ¼
triple antiplatelet therapy.
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937(OPR) was signiﬁcantly lower and the percentage of inhibi-
tion signiﬁcantly higher in the TAT group compared with the
DDAT group at 12 to 24 h after the loading dose (excludingTable 3. Clinical Outcomes at Discharge and at 1 Month
Endpoint
Cumulative Event Rate at
Discharge
TAT
(n ¼ 1,879)
DDAT
(n ¼ 1,876)
Primary endpoint 16 (0.9) 17 (0.9)
Secondary endpoints
Cardiac death 6 (0.3) 5 (0.3)
Nonfatal myocardial infarction 6 (0.3) 8 (0.4)
Periprocedural infarction 6 (0.3) 8 (0.4)
Spontaneous infarction 0 (0.0) 0 (0.0)
Stroke 2 (0.1) 3 (0.2)
Ischemic stroke 2 (0.1) 3 (0.2)
Stent thrombosis, deﬁnite or probable 2 (0.1) 2 (0.1)
Stent thrombosis, deﬁnite 1 (0.1) 0 (0.0)
Stent thrombosis, probable 1 (0.1) 2 (0.1)
PLATO major bleeding 3 (0.2) 4 (0.2)
Other events
All-cause death 6 (0.3) 8 (0.4)
PLATO minor bleeding 9 (0.5) 1 (0.1)
Target lesion revascularization 3 (0.2) 1 (0.1)
Target vessel revascularization 3 (0.2) 1 (0.1)
Values are n (%). The primary endpoint was deﬁned as a composite of cardiac death, nonfatal myocardi
values were calculated using Cox proportional hazards models for the triple antiplatelet therapy grou
Patient Outcomes (PLATO) major and minor bleeding was deﬁned according to the PLATO criteria.
Abbreviations as in Table 2.those treated with glycoprotein inhibitors) and at 1-month
follow-up after the maintenance dose, but there still was
a wide variability in the platelet reactivity (Fig. 5). The relativeCumulative Event Rate at
1 Month
Hazard Ratio (95% CI) p Value
TAT
(n ¼ 1,879)
DDAT
(n ¼ 1,876)
23 (1.2) 27 (1.4) 0.85 (0.49–1.48) 0.566
8 (0.4) 7 (0.4) 1.14 (0.41–3.15) 0.798
7 (0.4) 13 (0.7) 0.54 (0.21–1.35) 0.185
6 (0.3) 8 (0.4) 0.75 (0.26–2.16) 0.591
1 (0.1) 5 (0.3) 0.20 (0.02–1.71) 0.141
2 (0.1) 3 (0.2) 0.67 (0.11–3.99) 0.656
2 (0.1) 3 (0.2) 0.67 (0.11–3.99) 0.656
4 (0.2) 7 (0.4) 0.57 (0.17–1.95) 0.371
2 (0.1) 4 (0.2) 0.50 (0.09–2.73) 0.423
2 (0.1) 3 (0.2) 0.67 (0.11–3.99) 0.656
8 (0.4) 8 (0.4) 1.00 (0.38–2.66) 0.999
9 (0.5) 11 (0.6) 0.82 (0.34–1.97) 0.654
12 (0.6) 6 (0.3) 2.00 (0.75–5.34) 0.165
4 (0.2) 5 (0.3) 0.80 (0.22–2.98) 0.739
7 (0.4) 5 (0.3) 1.40 (0.44–4.41) 0.567
al infarction, stent thrombosis, stroke, and PLATO major bleeding at 1 month. Hazard ratios and p
p compared with the double-dose clopidogrel antiplatelet therapy group. Platelet Inhibition and
Figure 2. Cumulative Kaplan-Meier Estimates for the Primary Endpoint and PLATO Major Bleeding at 1 Month
Kaplan-Meier curves show the cumulative incidence of the net clinical outcome (the primary endpoint), a composite of cardiac death, nonfatal myocardial infarction,
stent thrombosis, stroke, or PLATO major bleeding (A) and PLATO major bleeding (B). Abbreviations as in Figure 1.
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938difference in OPR between TAT and DDAT, both after the
loading dose and at 1 month, was unchanged even after
multivariable adjustment for baseline factors (OnlineBA
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Figure 3. Landmark Analysis at 1 Week for the Primary Endpoint and Major Seco
Kaplan-Meier curves show the cumulative incidence of the primary endpoint (net clini
deﬁnite or probable stent thrombosis (E), and PLATO major bleeding (F) up to 1 weTable 4). In a plot of only the thrombotic events, a composite
of cardiac death, spontaneous MI, ischemic stroke, or stent
thrombosis, the OPR was >228 platelet reactivity units atC  
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ndary Endpoints
cal outcome) (A), cardiac death (B), nonfatal myocardial infarction (C), stroke (D),
ek and from 1 week to 1 month. Abbreviations as in Figure 1.
Figure 4. Hazard Ratios for the Primary Endpoint According to Allocated Treatment in Selected Subgroups
Forest plot of various subgroups regarding the primary endpoint (net clinical outcome) showing no signiﬁcant intergroup difference in the treatment effect of TAT
versus DDAT. CCB ¼ calcium channel blockers; CI ¼ conﬁdence interval; other abbreviations as in Figure 1.
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93912 to 24 h after the loading dose in all but 1 event. In
the 1 case in which a stroke occurred despite platelet reactivity
of 54 platelet reactivity units, the patient had an infectionFigure 5. On-treatment Platelet Reactivity
Scatterplot of on-treatment platelet reactivity in the TAT and DDAT groups at 12 to
Abbreviations as in Figure 1.with chronic renal failure, chronic obstructive pulmonary
disease, hypertension, dyslipidemia, signiﬁcant peripheral
artery disease, renal artery stenosis, and coronary artery disease24 h after a loading dose (A) and at 1 month after a maintenance dose (B).
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going PCI.
Discussion
In this prospective, randomized, multicenter trial, we found
that the adjunctive use of cilostazol for 1 month in addition
to conventional dual antiplatelet therapy was noninferior to
doubling the maintenance dose of clopidogrel with regard to
net clinical outcome. Furthermore, there were no differences
between the 2 treatment regimens regarding the individual
components of the primary outcome.
Potent inhibition of platelet reactivity during the ﬁrst
month after PCI is one of the key factors in a successful
outcome. It has been shown in various studies that HOPR
is associated with increased risk of thrombotic outcomes
(2–5,16), with the most profound association between
platelet reactivity and outcome seen in the ﬁrst month post-
PCI (1). Before the commercial launch of newer antiplatelet
agents with less variability such as prasugrel (17) and tica-
grelor (18), doubling the maintenance dose of clopidogrel to
150 mg was the approach used often in high-risk patients
such as those with MI, those with documented increased
platelet reactivity, and those with genetic risk such as the
CYP2C19 loss-of-function carriers (19–22). In the OPTI-
MUS (Optimizing Antiplatelet Therapy in Diabetes) trial,
doubling the maintenance dose of clopidogrel was more
potent in inhibiting platelet reactivity in patients with dia-
betes (23). In the ARMYDA (Atorvastatin for Reduction of
Myocardial Damage During Angioplasty) 150 mg random-
ized trial, DDAT was associated with higher platelet
inhibition, better ﬂow-mediated vasodilation, and lower
high-sensitivity C-reactive protein levels than conventional
dose clopidogrel therapy (24). Furthermore, in the
CURRENT–OASIS 7 trial, 1-week duration of doubling
the dose of clopidogrel was shown to improve clinical
outcome at 1 month compared with the conventional dose in
ACS patients undergoing PCI (7).
In the Republic of Korea, as a population, the rate of
HOPR exceeds 50% and the frequency of CYP2C19 LOF
carriers is >60% (5,25–27). Furthermore, PCI is per-
formed aggressively with left main artery stenting routinely
performed along with multivessel stenting. However, the
approach taken by physicians in East Asia in these situa-
tions is to add cilostazol as a third agent rather than to
increase the maintenance dose of clopidogrel. The basis of
adding cilostazol in the Republic of Korea comes from
pharmacodynamic studies from our group and others that
have shown that TAT signiﬁcantly enhances platelet
inhibition (8,9). In lesions requiring long stenting and in
diabetic patients, studies from the Republic of Korea have
reported superior outcomes of TAT over conventional dual
antiplatelet therapy regarding inhibition of neointima
formation and signiﬁcantly reduced rates of clinicallydriven target lesion revascularization (28,29). Furthermore,
in the post hoc analysis of the CILON-T (Inﬂuence of
CILostazol-based triple antiplatelet therapy ON ischemic
complication after drug-eluting stenT implantation) trial,
we showed that mean OPR was signiﬁcantly lower in TAT
compared with conventional dual antiplatelet therapy and
that there was a signiﬁcant trend toward a worse outcome
in those with high OPR. However, we could not observe
clinical beneﬁts of TAT in that study because the study
was underpowered to show differences in thrombotic
outcome (30). Regarding pharmacodynamics, TAT has
been shown to be more efﬁcacious with regard to inhibi-
tion of platelet reactivity in patients with documented
HOPR, patients with diabetes, patients with acute MI,
those with chronic kidney disease, and carriers of the
CYP2C19 loss-of-function allele, compared with DDAT
(11,12,31–33). However, there has been no large-scale
prospective study directly comparing clinical outcomes of
TAT and DDAT.
This study was performed to generate evidence of a
rationale for using TAT in high-risk situations as is done
by many Asian physicians by showing the noninferiority of
TAT compared with DDAT. In both intention-to-treat
and per-protocol analyses, the absolute rate of the primary
outcome was numerically lower in the TAT group, and the
1-sided 97.5% upper CI interval (0.34%) was within the
0.75% pre-speciﬁed noninferiority margin. The rates of
cardiac death and stroke were almost identical in the
2 groups. Regarding stent thrombosis and nonfatal MI,
there were also no statistical differences. However, events
occurred slightly less frequently in the TAT group. In the
per-protocol analysis, spontaneous MI only occurred in the
DDAT group with no events in the TAT group.
Regarding bleeding, the rate of PLATO major bleeding
was the same in the 2 groups, but the occurrence of
PLATO minor bleeding was numerically more frequent in
the TAT group, although this was not statistically signif-
icant. This may be explained by the results of a platelet
function substudy that showed signiﬁcantly lower OPR in
the TAT group. This could have led to the increased
minor bleeding, but not major bleeding. Previous studies
have shown that bleeding time was less affected by cil-
ostazol compared with other antiplatelet inhibitors (34,35).
It is thought that the elevation in cyclic adenosine
monophosphate levels initiated by cilostazol, a phosphodi-
esterase inhibitor, leads to the inhibition of activated
platelets at the site of vascular injury. In addition, another
study suggested that cilostazol does not affect thrombin
generation (36). In this study, we did not observe
any differences in treatment effect among various
subgroups including those with diabetes and those pre-
senting with ACS.
Study limitations. First, the event rates were extremely low
at 1 month and lower than expected from the original power
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941calculation. We had expected the occurrence of the primary
endpoint to be 3% in the DDAT arm when we designed the
study, and with a noninferiority margin of 0.75%, we would
have had a >90% power to show the noninferiority of TAT.
However, with the event rate being 1.4% in the control arm,
there is a chance that we would be accepting as high as
a 48% relative risk increase as being noninferior with the
number of patients enrolled in the present study. Therefore,
we acknowledge that our study is underpowered to
concretely prove that TAT is noninferior to DDAT. We
would have needed a signiﬁcantly larger population of
patients to prove noninferiority of TAT versus DDAT given
that the event rate of DDAT was 1.4% with a noninferiority
margin of a relative 25% (absolute 0.35%). Second, there
may be a chance of underreporting of events considering
the low event rate. However, we performed dedicated
periodic on-site monitoring of >30% of the source docu-
ments at each site. In addition, it is well-known that event
rates after PCI are lower in the East Asian population,
especially in the Republic of Korea and Japan (37,38). This
may be due to unknown genetic factors or may be in part due
to the fact that intravascular ultrasound is used much more
frequently in everyday practice in the Republic of Korea. In
fact, 40% of the patients received IVUS guidance during
PCI in the present study. It needs to be noted, in addition,
that this study population represents a lower-risk proﬁle
than that of the CURRENT–OASIS 7 trial, in which all the
patients had ACS and their event rates were shown to be
4.2% to 4.4%. Third, the periprocedural MI rates were also
very low. This may be because cardiac enzyme measurement
was only done in those with signiﬁcant chest discomfort and
otherwise left to the treating physicians’ discretion. It is likely
that had we measured cardiac enzymes in all patients, the
rates of periprocedural MI would be much higher. Finally,
adherence to allocated medication was only 91.6% and 86.5%
in the TAT and DDAT group, respectively, which may have
affected the outcomes. However, our results were identical
whether analyzed by the intention to treat or per protocol.Conclusions
Although the study was underpowered due to extremely low
event rates, the adjunctive use of cilostazol in addition to
conventional dual antiplatelet therapy showed comparable
rates of clinical outcome and seems to be noninferior to
doubling the maintenance dose of clopidogrel in this broad
PCI population receiving exclusively drug-eluting stents
with regard to net clinical outcome at 1 month.Acknowledgments
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